Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAdvisor Group Holdings, Inc.
Latest Disclosed Ownership46,653 shares
Latest Disclosed Value $ 15,436,057
Advisor Group Holdings, Inc. reports 4.33% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Advisor Group Holdings, Inc. filed a 13F-HR form disclosing ownership of 46,653 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $13,328,762 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 44,718 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 4.33% during the quarter. The current value of the position is $12,153,106 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 46,653 1,935 4.33 15,436 -13.20 0.0131
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,718 19,780 79.32 17,783 57.26 0.0260
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,938 21,151 558.52 11,309 841.55 0.0158
2025-09-04 2025-06-30 13F/A-1 LNYLAM PHARMACEUTICALS COM 02043Q107 3,787 2,158 132.47 1,202 173.58 0.0021
2025-08-13 2025-06-30 13F LNYLAM PHARMACEUTICALS COM 02043Q107 2,696 1,067 798 0.0009
2025-05-12 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,629 -3,200 -66.27 440 5.53 0.0010
2025-06-06 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 4,829 3,465 254.03 417 10.93 0.0009
2025-02-07 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,893 3,529 455 0.0012
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,364 174 14.62 375 29.76 0.0008
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,190 -373 -23.86 289 24.03 0.0007
2024-05-10 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,563 -2,032 -56.52 234 -66.08 0.0005
2024-02-12 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,595 -625 -14.81 688 -8.03 0.0012
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,220 182 4.51 747 -3.11 0.0011
2023-08-21 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 4,038 284 7.57 772 2.25 0.0014
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,038 284 772 0.0002
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,754 -2,301 -38.00 754 -47.57 0.0014
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,055 2,851 88.98 1,439 124.34 0.0029
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,204 -1,654 -34.05 641 -9.59 0.0015
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,858 -825 -14.52 709 -16.59 0.0016
2022-05-04 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,683 -165 -2.82 850 -14.49 0.0016
2022-02-03 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,848 418 7.70 994 -3.02 0.0019
2021-11-05 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,430 262 5.07 1,025 17.01 0.0021
2021-08-02 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,168 604 13.23 876 36.24 0.0019
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,564 2,313 102.75 643 120.21 0.0015
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,251 234 11.60 292 0.00 0.0008
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,017 333 19.77 292 18.22 0.0009
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,684 235 16.22 247 55.35 0.0008
2020-05-18 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,449 1,449 159 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.